Unlocking New Medicines
for Patients
Advancing the development of novel antidepressants and anxiolytics based on clinically validated mechanisms using our Glyph™ platform
Unlocking New Medicines
for Patients
Advancing the development of novel antidepressants and anxiolytics based on clinically validated mechanisms using our Glyph™- platform
Our proprietary
Glyph™ platform
is designed to bypass first-pass metabolism and enhance a drug’s oral bioavailability and reduce side effects
Our proprietary
Glyph™platform
is designed to bypass first-pass metabolism and enhance a drug’s oral bioavailability and reduce side effects
Prevalence of Depression and Anxiety
Large unmet need for new therapies
1. Mental disorders; World Health Organization, 2022; 2. Kessler et al., 2015. Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. Epidemiol Psychiatr Sci. 2015; 2. American Association of Suicidology, 2009; *MDD = Major Depressive Disorder; 3. Suicide Data and Statistics | Suicide Prevention | CDC. (n.d.). https://www.cdc.gov/suicide/suicide-data-statistics.html
We are passionate
about helping people living with depression, anxiety, and other debilitating neuropsychiatric disorders
We are passionate
about helping people living with depression, anxiety, and other debilitating neuropsychiatric disorders
An oral allopregnanolone prodrug bypasses liver metabolism via lymphatic transport enabling bioavailability in animals and humans
